ATE449842T1 - Anti-bambi antikörper oder rna zur diagnose und therapie bei dickdarm- oder leberkrebs - Google Patents

Anti-bambi antikörper oder rna zur diagnose und therapie bei dickdarm- oder leberkrebs

Info

Publication number
ATE449842T1
ATE449842T1 AT04735121T AT04735121T ATE449842T1 AT E449842 T1 ATE449842 T1 AT E449842T1 AT 04735121 T AT04735121 T AT 04735121T AT 04735121 T AT04735121 T AT 04735121T AT E449842 T1 ATE449842 T1 AT E449842T1
Authority
AT
Austria
Prior art keywords
bambi
liver cancer
colon
rna
antibodies
Prior art date
Application number
AT04735121T
Other languages
English (en)
Inventor
Tetsu Akiyama
Takashi Sekiya
Susumu Ohwada
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE449842T1 publication Critical patent/ATE449842T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04735121T 2003-05-28 2004-05-27 Anti-bambi antikörper oder rna zur diagnose und therapie bei dickdarm- oder leberkrebs ATE449842T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003151302 2003-05-28
PCT/JP2004/007677 WO2004106515A1 (ja) 2003-05-28 2004-05-27 抗ｂａｍｂｉ抗体、及びそれを含有する大腸癌及び肝臓癌の診断剤又は治療剤

Publications (1)

Publication Number Publication Date
ATE449842T1 true ATE449842T1 (de) 2009-12-15

Family

ID=33487216

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04735121T ATE449842T1 (de) 2003-05-28 2004-05-27 Anti-bambi antikörper oder rna zur diagnose und therapie bei dickdarm- oder leberkrebs

Country Status (6)

Country Link
US (1) US7491802B2 (de)
EP (1) EP1627916B1 (de)
JP (1) JP4705469B2 (de)
AT (1) ATE449842T1 (de)
DE (1) DE602004024300D1 (de)
WO (1) WO2004106515A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3129509B1 (de) * 2014-04-10 2020-06-17 Bio-Marcare Technologies Ltd. Verfahren und kits zur identifizierung von präkanzerösen kolorektalen polypen und kolorektalkrebs
ES2626491B1 (es) * 2015-12-03 2018-06-25 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpos monoclonales frente a bambi y uso para tratamiento de enfermedades inflamatorias
CN107267642B (zh) * 2017-07-28 2021-01-15 周小军 Bambi作为鼻咽癌标志物的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
US5635388A (en) * 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5747273A (en) * 1996-05-07 1998-05-05 Diagnostic Systems Laboratories, Inc. Immunoassay of total insulin-like growth factor binding protein-1
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP2000323499A (ja) 1999-05-10 2000-11-24 Hitachi Cable Ltd 化合物半導体エピタキシャルウェハ
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス， インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
KR100996226B1 (ko) * 2001-10-31 2010-11-24 유니버시티 오브 노스 텍사스 헬스 사이언스 센터 뼈 형태발생 단백질(ｂｍｐ), ｂｍｐ 수용체 및 ｂｍｐ결합 단백질 및 녹내장 진단 및 치료에서 그의 용도

Also Published As

Publication number Publication date
JPWO2004106515A1 (ja) 2006-07-20
EP1627916A4 (de) 2006-08-30
JP4705469B2 (ja) 2011-06-22
US7491802B2 (en) 2009-02-17
US20070065446A1 (en) 2007-03-22
EP1627916A1 (de) 2006-02-22
EP1627916B1 (de) 2009-11-25
WO2004106515A1 (ja) 2004-12-09
DE602004024300D1 (de) 2010-01-07

Similar Documents

Publication Publication Date Title
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
ATE408419T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
SG134283A1 (en) Biomarkers for liver fibrotic injury
WO2002032953A3 (en) Pregnancy-associated plasma protein-a2 (papp-a2)
JP4372340B2 (ja) アポトーシス関連化合物およびその使用
EP2030984A4 (de) Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält
BR0309638A (pt) Polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, ligando, composto, método de diagnóstico de uma doença em um paciente, uso de um polipeptìdeo, composição farmacêutica, composição de vacina, métodos de tratamento de uma doença em um paciente, de monitoração do tratamento terapêutico de doença em um paciente, e de identificação de um composto que é eficaz no tratamento e/ou no diagnóstico de doença, kit, animal não humano knockout ou transgênico, e, método para a seleção de um composto eficaz para o tratamento de doença
MX2021001507A (es) Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
DE60026733D1 (de) Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
DK1536006T3 (da) Cancerantigener og anvendelse deraf
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
DE60219645D1 (de) Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
ATE449842T1 (de) Anti-bambi antikörper oder rna zur diagnose und therapie bei dickdarm- oder leberkrebs
WO2004070012A3 (en) Cell-killing molecules and methods of use thereof
EP1580265A4 (de) Aus einem neuroblastom in stufe 4s isoliertenukleinsäuren
WO2002088378A3 (en) 66784, a novel human potassium channel and uses therefor
DE50312502D1 (de) Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen
WO2004042363A3 (en) In vivo imaging of e2f-regulated bioluminescent proteins
WO2002072626A3 (de) Neue form des phgpx-proteins als diagnostischer marker bei männlicher infertilität
WO2003087408A3 (en) Schizophrenia associated genes
WO2018156645A1 (en) Preventative cancer therapy
WO2005014645A3 (en) Pedf-r receptor and uses
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
WO2005090397A8 (de) Hyphenspezifische zellwandproteine von candida

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties